Why the study?
The contribution of genetic variants to non-ischemic sudden cardiac death due to acquired myocardial diseases was unclear.
Do potentially disease-associated gene variants contribute to non-ischemic sudden cardiac death in patients with hypertension/obesity-related hypertrophic myocardial disease?
Do potentially disease-associated gene variants contribute to non-ischemic sudden cardiac death in patients with hypertension/obesity-related hypertrophic myocardial disease?
Potentially disease-related gene variants are common in non-ischemic SCD victims with acquired hypertrophy, though their frequency was not statistically significantly higher than in living controls with hypertension and hypertrophy.
Variants common but not enriched vs controls; leaves open contribution to non-ischemic SCD in hypertensive hypertrophy.
The contribution of genetic variants to non-ischemic sudden cardiac death (SCD) due to acquired myocardial diseases is unclear. We studied whether SCD victims with hypertension/obesity related hypertrophic myocardial disease harbor potentially disease associated gene variants. The Fingesture study has collected data from 5869 autopsy-verified SCD victims in Northern Finland. Among SCD victims, 740 (13%) had hypertension and/or obesity as the most likely explanation for myocardial disease with hypertrophy and fibrosis. We performed next generation sequencing using a panel of 174 cardiac genes for 151 such victims with the best quality of DNA. We used 48 patients with hypertension and hypertrophic heart as controls. Likely pathogenic variants were identified in 15 SCD victims (10%) and variants of uncertain significance (VUS) were observed in additional 43 SCD victims (28%). In controls, likely pathogenic variants were present in two subjects (4%; p = 0.21) and VUSs in 12 subjects (25%; p = 0.64). Among SCD victims, presence of potentially disease-related variants was associated with lower mean BMI and heart weight. Potentially disease related gene variants are common in non-ischemic SCD but further studies are required to determine specific contribution of rare genetic variants to the extent of acquired myocardial diseases leading to SCD.
No takes yet. Share an insight, caveat, or question.
Holmström et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: